Tuesday17 Nov 2026
Isomorphic Labs raises $5B Series C to scale its AI drug design engine
Co-led on 17 November 2026 by Greenoaks and Sequoia Capital with Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
ResearchStory 11 of the day
60-second takeaway: Isomorphic Labs raises a $5 billion Series C round co-led by Greenoaks and Sequoia Capital to scale its IsoDDE drug design engine towards clinical trials.
Why it matters: Raising $5 billion gives Isomorphic Labs sovereign-biotech capital to fund wet-lab validation and human clinical trials on its own internal drug pipeline beyond pharma partnerships.
- Financing round and size
- $5 billion Series C announced on 17 November 2026 (post-money valuation undisclosed)
- Co-lead and new investors
- Co-led by Greenoaks and Sequoia Capital, joined by Andreessen Horowitz (a16z) and Alphabet
- Returning investors
- Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund

